Survival in thalassaemia major patients

Circ J. 2006 Aug;70(8):1037-42. doi: 10.1253/circj.70.1037.

Abstract

Background: The present study evaluated the prognostic significance of Doppler-demonstrated left ventricular (LV) restrictive filling pattern (RFP) in patients with thalassaemia major (TM), which carries an adverse cardiovascular prognosis.

Methods and results: The study group comprised 45 asymptomatic transfusion-dependent patients with TM and normal LV systolic function. All patients were chelated with desferrioxamine. They were regularly evaluated by clinical and Doppler-echocardiographic studies throughout the 15-year follow-up period. The patients were categorized into 2 groups according to baseline data: those with LVRFP and those with LV non-RFP. The incidence of cardiac death in both groups was analyzed. The impact of chelation therapy on the ventricular filling pattern and survival was also examined. Nineteen patients (42.2%) had LVRFP and 26 (57.8%) had LV non-RFP. During follow-up 11 patients died from cardiac causes; 8 of them (72.8%) initially had LVRFP and 3 (27.2%) had LV non-RFP. LVRFP was significantly associated with mortality (p=0.018). Poor compliance with chelation therapy was significantly associated with LVRFP (p=0.007) and cardiac mortality (p=0.003).

Conclusions: LVRFP is an important predictor of cardiac mortality in patients with TM. Poor compliance with chelation therapy was significantly associated with both a RFP (p=0.007) and cardiac mortality (p=0.003).

MeSH terms

  • Adolescent
  • Adult
  • Chelation Therapy
  • Death
  • Deferoxamine / therapeutic use
  • Echocardiography, Doppler
  • Female
  • Humans
  • Longitudinal Studies
  • Male
  • Predictive Value of Tests
  • Prognosis
  • Proportional Hazards Models
  • Siderophores / therapeutic use
  • Survival Analysis
  • Survival Rate
  • Ventricular Dysfunction, Left / diagnostic imaging*
  • Ventricular Dysfunction, Left / etiology*
  • beta-Thalassemia / complications*
  • beta-Thalassemia / drug therapy
  • beta-Thalassemia / mortality*

Substances

  • Siderophores
  • Deferoxamine